A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma
Glucocorticoids are the most widely used agents in the treatment of allergic bronchopulmonary aspergillosis (ABPA), a disorder characterised by immunologic reactions mounted against Aspergillus fumigatus colonising the airways of patients with asthma and cystic fibrosis [1, 2]. Unfortunately, the use of glucocorticoids is associated with several adverse reactions [3]. A novel treatment strategy in ABPA would be the use of antifungal triazoles as monotherapy. Recently, we have shown that itraconazole was effective as monotherapy in acute-stage ABPA [4]. Whether voriconazole monotherapy is also efficacious in acute-stage ABPA remains unknown.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Agarwal, R., Dhooria, S., Sehgal, I. S., Aggarwal, A. N., Garg, M., Saikia, B., Chakrabarti, A. Tags: Original Articles: Research letters Source Type: research
More News: Allergy & Immunology | Aspergillosis | Aspergillus | Asthma | Cystic Fibrosis | Prednisolone | Respiratory Medicine